Summit Therapeutics extends enrolment in phase 2 PhaseOut DMD study

This article was originally published here

Summit Therapeutics has opened enrolment in a planned additional group in its phase 2 open label clinical trial dubbed PhaseOut DMD for its Duchenne muscular dystrophy (DMD) drug ezutromid.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply